glp 1 gila monster Diabetes drug from venom We're all here because of
Description
When considering weight loss drugs from an underwriting perspective, we need to continue to take a comprehensive approach and to think critically about the broader implications of these drugs in the context of obesity management and overall health strategies
Beyond working with a doctor to ensure nutritional benchmarks are met, the recommendations include screening for a history of disordered eating and taking into account a persons whole health before prescribing
These requirements mirror those that may have limited adoption of Rybelsus, the oral semaglutide from Novo Nordisk approved for diabetes in 2019
Visual resources like this should be standardized as clinic leaflets and given routinely at GLP-1 initiation
Huang KP, Acosta AA, Ghidewon MY, McKnight AD, Almeida MS, Nyema NT, et al
